



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 765 163 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- (15) Correction information:
Corrected version no 1 (W1 B1)
INID code(s) 73
- (48) Corrigendum issued on:
08.03.2006 Bulletin 2006/10
- (45) Date of publication and mention
of the grant of the patent:
07.12.2005 Bulletin 2005/49
- (21) Application number: **95921672.2**
- (22) Date of filing: **15.06.1995**
- (51) Int Cl.:
A61K 33/06 ^(1985.01) **A61K 39/09** ^(1985.01)
A61K 39/10 ^(1985.01) **A61K 39/155** ^(1985.01)
A61K 39/145 ^(1985.01) **A61K 39/20** ^(1985.01)
A61P 37/00 ^(2000.01)
- (86) International application number:
PCT/CA1995/000359
- (87) International publication number:
WO 1995/034308 (21.12.1995 Gazette 1995/54)

(54) **ADJUVANT COMPOSITIONS COMPRISING A MINERAL SALT AND ANOTHER IMMUNOSTIMULATING COMPOUND**

IMMUNSTIMULIERENDE ZUSAMMENSETZUNGEN DIE EIN MINERALES SALZ UND EIN WEITERES ADJUVANT ENTHALTEN

COMPOSITIONS D'ADJUVANT COMPRENANT UN SEL MINERAL ET UN AUTRE COMPOSE IMMUNOSTIMULATEUR

- | | |
|--|---|
| <p>(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE</p> <p>(30) Priority: 16.06.1994 US 261194</p> <p>(43) Date of publication of application:
02.04.1997 Bulletin 1997/14</p> <p>(60) Divisional application:
05023779.1</p> <p>(73) Proprietor: Sanofi Pasteur Limited
Toronto, Ontario M2R 3T4 (CA)</p> <p>(72) Inventors:
• KANDIL, Ali
Willowdale, Ontario M2R 1A1 (CA)
• JAMES, Olive, A.
Toronto, Ontario M6M 5B3 (CA)
• CHONG, Pele
Richmond Hill, Ontario L4C 0B6 (CA)
• KLEIN, Michel, H.
Willowdale, Ontario M2P 1B9 (CA)</p> | <p>(74) Representative: Smart, Peter John et al
Beck Greener
Fulwood House,
12 Fulwood Place,
London WC1V 6HR (GB)</p> <p>(56) References cited:
EP-A- 0 445 710 US-A- 4 258 029
US-A- 4 855 283</p> <ul style="list-style-type: none">• DATABASE WPI Week 9323 Derwent Publications Ltd., London, GB; AN 93-185171 & JP,A,05 112 466 (SHIONOGI & CO) , 7 May 1993• J. IMMUNOL., vol. 144, no. 12, 1990 pages 4798-4802, A.NIXON-GEORGE ET AL. 'The adjuvant effect of stearyl tyrosine on a recombinant subunit hepatitis b surface antigen.' cited in the application• BIOLOGICALS, vol. 22, no. 1, 1994 pages 53-63, R.K. GUPTA ET AL 'comparison of adjuvant activities of aluminium phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid.'• PROG. LEUKOCYTE BIOL., vol. 9, 1989 pages 575-579, K.G. STUENKEL ET AL. 'Synthetic glycolipids with immunopotentiating activity on humoral immunity: evaluation in vivo.' |
|--|---|

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 765 163 B8